Long-term safety of filgrastim (rhG-CSF) administration.
about
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsBone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for haematological malignanciesAcute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor ProgramAllogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).Allogeneic peripheral blood stem cell collection as of 2008.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Protecting the Health and Safety of Cell and Tissue DonorsEffects and safety of granulocyte colony-stimulating factor in healthy volunteersSafeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone.Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma.The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors.G-CSF in Healthy Allogeneic Stem Cell Donors.Colony-stimulating factors for febrile neutropenia during cancer therapy.Long-term toxic effects of adjuvant chemotherapy in breast cancer.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies.Eighteen years experience of granulocyte donations-acceptable donor safety?Inflammatory markers, oxidative stress, and antioxidant capacity in healthy allo-HSCT donors during hematopoietic stem cell mobilization.Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.Volunteer unrelated donor experience after administration of filgrastim and apheresis for the collection of haemopoietic stem cells: the Australian perspective.Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch single-center cohort study.To G or not to G: is this still a question in allogeneic transplantation?Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models.
P2860
Q24195048-A1933DB6-CBBB-4668-B821-5EBA777C13AEQ24197741-4D06047A-9994-46B0-85A9-71417D085031Q33161966-BBA01D0B-67E4-4DCB-88CB-A96D02F81C58Q34330585-6981A4B1-8C42-435C-8F65-438369F83465Q35154218-D974095A-B645-4B3B-930A-38C95FF95E03Q35490056-C5EB1996-3371-4E78-AD3A-FA130B6DC8FCQ35551560-ACB93DC1-6404-4AF9-B359-519799EB6268Q35679682-C2C74464-D0EF-43BB-A540-9BF65AE6B96FQ36162892-2FB913B9-961A-483B-B303-587B2F2BFDA5Q36180365-E6DF0BD7-2E52-4FCB-8221-A99B8CDA9165Q36479390-D7319CB1-3E23-48F5-9098-06124F8BEC18Q36847551-4222A4B5-91B1-4C11-86C2-52E6EDE1F6C0Q36936723-D4085FAD-B743-499D-BAF0-E085F931F236Q37121877-802FFF60-9C97-4400-9CCE-2B7F4ECCBBA8Q37180718-A9F52E89-D111-4183-8137-1E025699EE9BQ37626772-16C22BAE-8614-4802-A6B6-A05A3E50DBE7Q37834884-863DF7D7-A2A9-4B94-9C95-C8E82C84000CQ37996560-0145A0B4-8473-45C9-B28A-59F4C133FFA8Q38323097-FAA55C0C-0823-49CF-A5B7-8FC22E1EA797Q41577983-88554FFB-1A0D-46ED-B842-D87735130C45Q42466472-5432255D-5208-458F-85FE-58CDE49EBF9EQ42783305-966FC76E-A0BC-422E-B335-F1EA81177173Q46661360-E4946CBD-382D-4F7E-9B19-CD8D95F0C809Q47815315-1C948662-038D-41AA-B314-0EC5A61995ABQ51772784-216A0884-D554-473A-8526-AF64B501B759Q52598486-F0FFE8DF-842B-4A2E-922B-F6B249D5C8FC
P2860
Long-term safety of filgrastim (rhG-CSF) administration.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Long-term safety of filgrastim (rhG-CSF) administration.
@ast
Long-term safety of filgrastim (rhG-CSF) administration.
@en
type
label
Long-term safety of filgrastim (rhG-CSF) administration.
@ast
Long-term safety of filgrastim (rhG-CSF) administration.
@en
prefLabel
Long-term safety of filgrastim (rhG-CSF) administration.
@ast
Long-term safety of filgrastim (rhG-CSF) administration.
@en
P2860
P1476
Long-term safety of filgrastim (rhG-CSF) administration.
@en
P2093
Dennis L Confer
John P Miller
P2860
P304
77-8; author reply 79-80
P356
10.1111/J.1365-2141.2007.06524.X
P407
P577
2007-04-01T00:00:00Z